Company to Focus on Pancreatic Cancer Detection Business in the U.S., Strategic Asset Sales and Future Strategic ...

Mainz Biomed (NASDAQ: MYNZ) on Tuesday said that it entered into a securities purchase agreement for a $6.0 million private placement with investor David Lazar, aimed at strengthening liquidity and ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Mainz Biomed B.V. ( (MYNZ)) has ...

BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce ...

BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...

Mainz Biomed NV has announced that it has regained compliance with Nasdaq's minimum stockholders’ equity requirement, confirming its continued listing on the Nasdaq Capital Market. This follows the ...

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 01.10.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement ...

Molecular genetics diagnostic company Mainz (Germany) Biomed has submitted an application for breakthrough device designation from the FDA for a colorectal cancer screening test. If granted, the ...

Mainz Biomed and Thermo Fisher Scientific signed a collaboration agreement for the development of the Company’s next generation colorectal cancer (CRC) screening product for global markets. The ...

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in ...

Maxim Group LLC is acting as the sole placement agent for the offering. Pick the best stocks and maximize your portfolio: Published first on TheFly – the ultimate source for real-time, market-moving ...

From expanding partnerships to advancing trials, Mainz Biomed NV (NASDAQ:MYNZ), the molecular genetics diagnostic company, had a busy 2024 – which appears to have shown in its revenue growth. The ...